Drug Profile
Gedivumab - Genentech
Alternative Names: Gedivumab; MHAA-4549A; RG 7745; RO 6876802Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 30 Jan 2020 Discontinued - Phase-II for Influenza A virus infections (Combination therapy) in Mexico, Taiwan, Russia, Sweden, Italy, Peru, Netherlands, Israel, South Africa, Ukraine, Spain, Poland, New Zealand, Hungary, Hong Kong, France, Chile, Bulgaria, Brazil, Germany, Czech Republic, Belgium, Canada, United Kingdom (IV) before January 2020
- 30 Jan 2020 Discontinued - Phase-II for Influenza A virus infections (Monotherapy) in New Zealand, South Korea, South Africa, Spain, United Kingdom, Canada, USA (IV) before January 2020
- 21 Apr 2018 Efficacy and adverse events data from a phase IIb trial in Influenza-A virus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)